Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
naltrexone + bupropion + topiramate
- Development stage
- Unknown
- Lead developer
- Currax Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CT-101 is an investigational fixed-dose combination therapy being developed by Currax Pharmaceuticals for the treatment of obesity. It is a "triple combination" product consisting of three FDA-approved small molecules: naltrexone, bupropion, and topiramate. Naltrexone is an opioid antagonist and bupropion is an aminoketone antidepressant that acts as a norepinephrine-dopamine reuptake inhibitor; together, they are already marketed by Currax as Contrave, which targets the brain's reward system and the hypothalamus to reduce food cravings and appetite. The addition of topiramate, an antiepileptic medication, is intended to enhance weight loss through its effects on GABAergic signaling, carbonic anhydrase inhibition, and modulation of glutamate receptors and sodium channels. CT-101 is designed to provide a multi-pathway approach to weight management and is currently undergoing Phase 2 clinical evaluation.
- Other names
- naltrexone/bupropion/topiramate
02
Targets
GABRR (GABA-A receptor subunit rho)CA (Carbonic anhydrase)DAT (Dopamine plasma membrane transport protein)GRIK1 (Glutamate ionotropic receptor kainate type subunit 1)NET (Norepinephrine Transporter)NaV (Voltage-gated sodium channels)MOR (Mu opioid receptor)GABA-B (Gamma-aminobutyric acid receptor type B)
Beyond the preview
Go deeper on naltrexone + bupropion + topiramate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on naltrexone + bupropion + topiramate.